Dr. Alpan is an internationally known industrial leader and academician with 25+ years of academic experience in Clinical Pharmacology and Molecular Pharmacology in the first rank medical schools in Turkey and the US and 20+ years of industry experience in biotechnology and pharmaceuticals. Based on his strong scientific background and entrepreneurial spirit, he built up a successful track record throughout his biopharmaceutical industry career on corporate and business development, long-range planning and strategy development, team-building, pipeline and portfolio strategy, alliance management, product and technology licensing, and co-development partnering, intellectual property, biopharmaceutical processing, preclinical and clinical development, regulatory submissions and approvals, biopharmaceutical facility design, construction, CMC, GMP, and validation.Main competencies and achievements include;• Strong scientific and technical background in molecular and clinical pharmacology and medical biotechnology.• Excellent leadership and organizational skills, leading and working effectively in cross-functional teams and managing multiple projects and processes in academia and industry.• International industrial experience and network with proven track records in biologics and small molecule drug development, production, CMC, and GMP.• Design and management of clinical studies according to local and international guidelines.• Leading founder of the Pharmacology Department at Yeditepe University Medical School.• Co-founder and President of TURGUT Biotechnology Group, the first world-class R&D-based, a fully integrated biotechnology company in Turkey for developing and manufacturing therapeutic monoclonal antibodies.• Founder of Turkey's first fully integrated Biotechnology R&D Center within the Campus of Acıbadem University to develop and produce therapeutic monoclonal antibodies. • Co-founder and President of TNC Pharmaceuticals, one of the first R&D-based clinical CROs in Turkey focused on design and performing global standard Phase I/ bioequivalence to Phase IV studies and regulatory affairs for local and international sponsors.